Potential of nanotechnology as a delivery platform against tuberculosis: Current research review

Journal of Controlled Release

Volumn 202, Issue , 2015, Pages 65-75

  Choudhary, S ^a   Kusum Devi, V ^a  

^a AL AMEEN COLLEGE OF PHARMACY   (India)

Author keywords

Diagnostic nanotechnology; Gene delivery; Therapeutic nanotechnology; Tuberculosis; Vaccine nanotechnology

Indexed keywords

CONTROLLED DRUG DELIVERY; GENE THERAPY; GENE TRANSFER; NANOTECHNOLOGY; NATURAL POLYMERS; VACCINES; YARN;

GENE DELIVERY; OPTIMIZED METHODOLOGIES; PREPARATION OF NANOPARTICLES; PRIME FIELD; RESEARCH REVIEW; RESISTANT STRAINS; THERAPEUTIC RESEARCH; TUBERCULOSIS;

TARGETED DRUG DELIVERY;

BCG VACCINE; CARBON NANOTUBE; ORGANIC SOLVENT; POLYMER; TUBERCULOSTATIC AGENT;

ARTICLE; DIRECTLY OBSERVED THERAPY; DRUG DELIVERY SYSTEM; DRUG ISOLATION; DRUG SPECIFICITY; DRUG TARGETING; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; NANOTECHNOLOGY; NANOTOXICOLOGY; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS; ANIMAL; MULTIDRUG RESISTANCE;

ANIMALS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; NANOTECHNOLOGY; TUBERCULOSIS; TUBERCULOSIS VACCINES;

EID: 84922513524     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.01.035     Document Type: Review

References (77)

1. K.C. Smith Tuberculosis in children Curr. Probl. Pediatr. 2001 5 30
2. M. Joe, Y. Bai, R.C. Nacario, and T.L. Lowary Synthesis of the docosanasaccharide arabinan domain of mycobacterial arabinogalactan and a proposed octadecasaccharide biosynthetic precursor J. Am. Chem. Soc. 129 2007 9885 9901
3. L.C.Du. Toit, V. Pillay, and M.P. Danckwerts Tuberculosis chemotherapy: current drug delivery approaches Respir. Res. 7 2006 118
4. Division of Tuberculosis Elimination Report - 2012 2012 Centers for Disease Control and Prevention (CDC) Atlanta, USA
5. R. Shegokar, L. Al Shaal, and K. Mitri Present Status of Nanoparticle Research for Treatment of Tuberculosis J. Pharm. Pharm. Sci. 14 2011 100 116
6. D. Thassu, Y. Pathak, and M. Deleers Nanoparticulate Drug-Delivery Systems: An Overview 1st edition 2000 Informa Healthcare
7. A. Zahoor, S. Sharma, and G.K. Khuller Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis Int. J. Antimicrob. Agents 26 2005 298 303
8. World Health Organization Global TB Report-2013 2013 WHO Library Cataloguing-in-Publication Data
9. Revised National TB Control Programme (RNTCP) Annual Report - 2013, Central TB Division (CTD) 2013 Directorate General of Health Sciences
10. India - Tuberculosis Profile - 2014 2014 World Health Organization Data
11. Multidrug-resistant Tuberculosis (MDR-TB) - 2013 Update 2013 WHO (GTB number C7)
12. S. Royce, and M. Grzemska Treatment of Tuberculosis Guidelines 4th ed. 2009 1 97
13. S. Gelperina, K. Kisich, M.D. Iseman, et al. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis Am. J. Respir. Crit. Care Med. 172 2005 1487 1490
14. M. Rajan, and V. Raj Encapsulation, characterization and in-vitro release of anti-tuberculosis drug using chitosan-polyethylene glycol nanoparticles Int. J. Pharm. Pharm. Sci. 4 2012 255 259
15. R. Pandey, S. Sharma, and G.K. Khuller Oral solid lipid nanoparticle-based antitubercular chemotherapy Tuberculosis 85 2005 415 420
16. K. Kataoka, A. Harada, and Y. Nagasaki Block copolymer micelles for drug delivery: design, characterization and biological significance Adv. Drug Deliv. Rev. 74 2001 113 131
17. D.A. Tomalia Birth of new molecular architecture: dendrimers as quantized building blocks for nanoscale synthetic polymer chemistry Prog. Polym. Sci. 30 2005 294 324
18. B.D. Chithrani, A.A. Ghazani, and W.C.W. Chan Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells Nano Lett. 6 2006 662 668
19. G.N. Kreytsberg, I.E. Gracheva, B.S. Kibrik, et al. Antituberculous effect of silver nanoparticles J. Phys. Conf. Ser. Nanotechnol. Int. Forum 291 2011 1 7
20. B.E. Rabinow Nanosuspensions in drug delivery Nat. Rev. Drug Discov. 3 2004 785 796
21. V. Raichur, and V. Kusum Devi Potential of targeted drug delivery system for the treatment of bone metastasis Drug Deliv. 19 2014 1 9
22. U.V. Bhosale, V. Kusum Devi, and S. Choudhary Development and in vitro-in vivo evaluation of oral drug delivery system of acyclovir loaded PLGA nanoparticles Int. J. Drug Deliv. 5 2013 331 343
23. U.V. Bhosale, V. Kusum Devi, and S. Choudhary Multiunit floating drug delivery system of acyclovir: development, characterization and in vitro-in vivo evaluation of spray-dried hollow microspheres J. Drug Del. Sci. Tech. 22 2012 548 554
24. P.S. Pourshahab, K. Gilani, E. Moazeni, et al. Preparation and characterization of spray dried inhalable powders containing chitosan nanoparticles for pulmonary delivery of isoniazid J. Microencapsul. 28 2011 605 613
25. R. Cassano, S. Trombino, T. Ferrarelli, et al. Synthesis, characterization and in-vitro antitubercular activity of isoniazid-gelatin conjugate J. Pharm. Pharmacol. 2012 1 7
26. G.K. Saraogi, P. Gupta, U.D. Gupta, et al. Gelatin nanocarriers as potential vectors for effective management of tuberculosis Int. J. Pharm. 385 2010 143 149
27. Z. Ahmad, R. Pandey, S. Sharma, et al. Novel chemotherapy for tuberculosis: chemotherapeutic potential of econazole- and moxifloxacin-loaded PLG nanoparticles Int. J. Antimicrob. Agents 31 2008 142 146
28. M. Gajendiran, V. Gopi, C. Elangovan, et al. Isoniazid loaded core shell nanoparticles derived from PLGA-PEG-PLGA tri-block copolymers: in vitro and in vivo drug release Colloids Surf. B: Biointerfaces 104 2013 107 115
29. G.K. Khuller, R. Pandey, A. Sharma, et al. Poly(dl-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis J. Antimicrob. Chemother. 52 2003 981 986
30. R. Pandey, and G.K. Khuller Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model J. Antimicrob. Chemother. 54 2004 266 268
31. R. Pandey, and G.K. Khuller Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis Tuberculosis 85 2005 227 234
32. K. Ohashi, K. Kabasawa, T. Ozeki, et al. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis J. Control. Release 135 2009 19 24
33. B. Lacramioara, A. Vasilica, V. Liliana, et al. Polymer nanoparticles for release of rifampicin Am. Sci. Pub. 5 2013 96 104
34. A. Behera, B.B. Barik, S. Pandya, et al. Formulation and evaluation of isoniazid loaded-∑-polycaprolactone nanoparticles J. Pharm. Res. 5 2012 798 802
35. K.O. Kisich, S. Gelperinaa, M.P. Higgins, et al. Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis Int. J. Pharm. 345 2007 154 162
36. T.P. Thomas, A.K. Patri, A. Myc, et al. In vitro targeting of synthesized antibody-conjugated dendrimer nanoparticles Biomacromolecules 5 2004 2269 2274
37. M. Kamat, K. El-Boubbou, D.C. Zhu, et al. Hyaluronic acid immobilized magnetic nanoparticles for active targeting and imaging of macrophages Bioconjug. Chem. 21 2010 2128 2135
38. B.K. Patel, R.H. Parikh, and P.S. Aboti Development of oral sustained release rifampicin loaded chitosan nanoparticles by design of experiment J. Drug Deliv. 2013 1 10
39. A. Sharma, S. Sharma, and G.K. Khuller Lectin-functionalized poly(lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis J. Antimicrob. Chemother. 54 2004 761 766
40. F. Yu, J. Wang, J. Dou, et al. Nanoparticle-based adjuvant for enhanced protective efficacy of DNA vaccine Ag85A-ESAT-6-IL-21 against Mycobacterium tuberculosis infection Nanomed. Nanotechnol. 8 2012 1337 1344
41. B. Carrillo-Conde, E.H. Song, Y. Phanse, et al. Mannose-functionalized "pathogen-like" polyanhydride nanoparticles target C-type lectin receptors on dendritic cells Mol. Pharm. 8 2011 1877 1886
42. J. Park, W. Gao, R. Whiston, et al. Modulation of CD4 + T lymphocyte lineage outcomes with targeted, nanoparticle-mediated cytokine delivery Mol. Pharm. 8 2010 143 152
43. M. Ballester, C. Nembrini, N. Dhar, et al. Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis Vaccine 29 2011 6959 6966
44. M. Bivas-Benita, S. Romeijn, H.E. Junginger, et al. PLGA-PEI nanoparticles for gene delivery to pulmonary epithelium Eur. J. Pharm. Biopharm. 58 2004 1 6
45. Y.L. Wong, S. Sampson, W.A. Germishuizen, et al. Drying a tuberculosis vaccine without freezing PNAS 104 2007 2591 2595
46. D.C. Maclurcan Nanotechnology and developing countries part 1: what possibilities? AZoNano 1 2005
47. P.C. Soo, Y.T. Horng, K.C. Chang, et al. A simple gold nanoparticle probes assay for identification of Mycobacterium tuberculosis and Mycobacterium tuberculosis complex from clinical specimens Mol. Cell. Probes 23 2009 240 246
48. H. Lee, T.J. Yoon, and R. Weissleder Ultrasensitive detection of bacteria using core-shell nanoparticles and an NMR-filter system Angew. Chem. Int. Ed. 48 2009 5657 5660
49. R. Martins, P. Baptista, L. Raniero, et al. Amorphous/nanocrystalline silicon biosensor for the specific identification of unamplified nucleic acid sequences using gold nanoparticle probes Appl. Phys. Lett. 90 2007 (023903-1-3)
50. E. Torres-Chavolla, and E.C. Alocilja Nanoparticle based DNA biosensor for tuberculosis detection using thermophilic helicase-dependent isothermal amplification Biosens. Bioelectron. 26 2011 4614 4618
51. K.H. Cheng, J. Aijmo, L. Ma, et al. Luminescence decay dynamics and trace biomaterials detection potential of surface-functionalized nanoparticles J. Phys. Chem. 112 2008 17931 17939
52. I.Y. Saleem, M. Vordermeier, J.E. Barralet, et al. Improving peptide-based assays to differentiate between vaccination and Mycobacterium bovis infection in cattle using nanoparticle carriers for adsorbed antigens J. Control. Release 102 2005 551 561
53. D.G. Russel, C.E. Barry, J.L. Flynn, et al. Tuberculosis: what we don't know can, and does, hurt us Science 2010 328
54. M.E. Hanley, H. Carolyn, et al. Current Diagnosis & Treatment in Pulmonary Medicine 53rd ed. 2014 Mc. Graw. Hill Pub.
55. A. Mwinga Drug resistant tuberculosis in Africa Acad. Sci. 953 2001 106 112
56. E.D. Chan, and M.D. Iseman Current medical treatment for tuberculosis Br. Med. J. 325 2002 1282 1286
57. M.D. Iseman Treatment of multidrug-resistant tuberculosis N. Engl. J. Med. 329 1993 784 791
58. S.K. Sharma, and A. Mohan Scientific basis of directly observed treatment, short course (DOTS) J. Indian Med. Assoc. 101 2003 157 158
59. R.F. Jacaban Multiple drug resistant tuberculosis Clin. Infect. Dis. 19 1994 1 10
60. J. Johnson, A. Kagal, and R. Bharadwaj Factors associated with drug resistance in pulmonary tuberculosis Indian J. Chest Dis. Allied Sci. 45 2003 105 109
61. M. Kato-Maeda, J.T. Rhee, T.S. Gingeras, et al. Comparing genomes within the species Mycobacterium tuberculosis Genome Res. 11 2001 547 555
62. S.K. Sharma, and A. Mohan Multidrug-resistant tuberculosis Indian J. Med. Res. 120 2004 354 376
63. R. Prasad MDR TB: current status Indian J. Tuberc. 52 2005 121 131
64. K. Floyd, R. Hutubessy, Y. Samyshkin, et al. Health-systems efficiency in the Russian Federation: tuberculosis control Bull. WHO 84 2006 43 51
65. S.K. Sharma, and A. Mohan Multidrug-resistant tuberculosis: a menace that threatens to destabilize tuberculosis control Chest 130 2006 261 272
66. E. Aboutaleb, M. Noorie, M. Gandomi, et al. Improved antimycobacterial activity of rifampin using solid lipid nanoparticles Int. Nano Lett. 2 2012 1 8
67. C.A. Raj, K.P. Senthil, K.K. Sathish, et al. Kinetics and drug release studies of isoniazid encapsulated with PLA-Co-PEG/Gold nanoparticles Int. J. Pharm. Pharm. Sci. 4 2012 398 404
68. R. Pandey, and G.K. Khuller Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model J. Antimicrob. Chemother. 57 2006 1146 1152
69. J. Chuan, Y. Li, L. Yang, et al. Enhanced rifampicin delivery to alveolar macrophages by solid lipid nanoparticles J. Nanoparticle Res. 15 2013 1 9
70. G.K. Saraogi, B. Sharma, B. Joshi, et al. Mannosylated gelatin nanoparticles bearing isoniazid for effective management of tuberculosis J. Drug Target. 19 2011 219 227
71. G. Radha, B. Ambarasan, V.A. Niranjana, et al. Relative study between isoniazid loaded chitosan with the gold encapsulated with isoniazid loaded chitosan nanoparticles Indo Am. J. Pharm. Res. 3 2013 4597 4604
72. R. Nair, K.V. Priya, M. Sevukarajan, et al. Formulation and evaluation of solid lipid nanoparticles of water soluble drug: isoniazid J. Pharm. Sci. Res. 3 2011 1256 1264
73. S.C. Derrick, A.L. Yang, and S.L. Morris A polyvalent DNA vaccine expressing an ESAT6-Ag85B fusion protein protects mice against a primary infection with Mycobacterium tuberculosis and boosts BCG-induced protective immunity Vaccine 23 2004 780 788
74. C. Palma, E. Iona, F. Giannoni, et al. The LTK63 adjuvant improves protection conferred by Ag85B DNA-protein prime-boosting vaccination against Mycobacterium tuberculosis infection by dampening IFN-Υ response Vaccine 26 2008 4237 4243
75. + T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection Infect. Immun. 2006 3396 3407
76. M. Havenga, R. Vogels, D. Zuijdgeest, et al. Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells J. Gen. Virol. 87 2006 2135 2143
77. E. Guzman, C. Cubillos-Zapata, M.G. Cottingham, et al. Modified vaccinia virus Ankara-based vaccine vectors induce apoptosis in dendritic cells draining from the skin via both the extrinsic and intrinsic Caspase pathways, preventing efficient antigen presentation J. Virol. 86 2012 5452 5466